LX-2343 improves cognitive dysfunction in APP/PS1 transgenic mice through the inhibition of Aβ accumulation and the promotion of Aβ clearance. This anti-amyloid effect shows LX-2343’s potential as a therapy for Alzhimer’s disease. LX-2343 reduces neuronal apoptosis by alleviating oxidative stress and inhibiting JNK/p38 and pro-apoptotic pathways. It also shows activity as a non-ATP competitive GSK-3β inhibitor.
| Cas No. | 333745-53-2 |
|---|---|
| Purity | ≥98% |
| Formula | C22H19ClN2O6S |
| Formula Wt. | 474.91 |
| IUPAC Name | N-1,3-Benzodioxol-5-yl-N2-(5-chloro-2-methoxyphenyl)-N2-(phenylsulfonyl)glycinamide |
| Synonym | LX2343 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Guo X., Sun G., et al. Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance. Acta Pharmacol Sin. 37(10):1281-1297 (2016). PMID:27569389.
Guo X., Sung G., et al. LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy. Acta Pharmacol Sin. 38(8):1104-1119 (2017). PMID:28649128.
